User login
Sponsored Links

Hodgkin's Chemotherapy: Stanford V

Stanford V is a chemotherapy regimen currently in clinical trials at Stanford Medical Center for Hodgkin's Lymphoma / Disease. Seven different chemotherapy drugs are administered over a shorter period of time, but more frequently, than standard chemotherapy regimens such as MOPP or ABVD. It is believed that this regimen will prove to be at least as effective as ABVD, while being better tolerated and having fewer long term side effects.

The drugs in the regimen:

Mechlorethamine (Mustargen) by vein once every 4 weeks
Doxorubicin (Adriamycin) by vein every odd week
Vinblastine (Velban) by vein every odd week
Vincristine (Oncovin) by vein every even week
Bleomycin (Blenoxane) by vein every even week
Etoposide (VP-16) by vein 2 days in a row weeks 3, 7, 11
Prednisone by mouth every other day


There are also other drugs prescribed to help with side effects and to prevent mouth sores and infection.

Effectiveness:

In trials from May 1989 to August 1995, 94 previously untreated patients with Hodgkin's disease (28 stage II bulky disease, and 66 stage III or IV) received Stanford V chemotherapy for 12 weeks with and without radiation therapy. With a median follow-up of 3 years, the actuarial 6-year survival was 93% and the freedom from progression 89%. There had been no relapses or deaths among the 28 patients with stage II bulky mediastinal disease. Eight relapses and three deaths occurred in the group of 66 patients with stage III-IV disease. Lower cumulative exposure to alkylating agents, doxorubicin, bleomycin and limited use of radiation is expected to improved the prospects for fertility and decrease the risks for secondary cancers and hear t problems.

Side Effects:

See information on individual chemotherapy agents for side effects. Again the trial organizers hope that side effects are reduced compared to ABVD.

 

Sponsored Links

 

Resources

Study Center(s):


Stanford University Medical Center

Current Study (1/2004)
Stanford Hospital and Clinics


Links for more information on Stanford V:


NCBI PubMed: J Clin Oncol 2002 Feb 1;20(3):607-9 Horning SJ et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
Mike Lach's Stanford V Page
Li's Pages - Stanford V


Experiences


Mike Lach's Hodgkins Page
Send Yours In

 

Related Articles

For more information on Adult Hodgkin's Disease, please see the following pages:


Hodgkin's Disease: Chemotherapy
Hodgkin's Disease: Treatment
Hodgkin's Disease: Resources
Hodgkin's Disease: Diagnosis
Hodgkin's Disease (Main Page)
Bone Marrow / Peripheral Blood Stem Cell Transplants


Other pages you may want to visit:


Lymphoma Information Network
Childhood Hodgkin's Disease Information Pages

 

Books

Books on Lymphoma Treatment including chemotherapy
Sponsored Links
Poll
What is most important to you in an Online Support Group?:
Latest Blog Entries

Did You Know?
Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Incidence rates for Hodgkin’s disease have declined about 60%. Better means of diagnosis has also increased the number as doctors better understand cancer of lymphocytes verses other diseases.